Lyell Immunopharma, Inc.
LYEL
$22.31
$1.507.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 87.50% | 14.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 87.50% | 14.29% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 87.50% | 14.29% | |||
| SG&A Expenses | 9.21% | -30.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -18.91% | 5.11% | |||
| Total Operating Expenses | -13.94% | -22.78% | |||
| Operating Income | 13.96% | 22.79% | |||
| Income Before Tax | 8.99% | 18.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.99% | 18.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.99% | 18.22% | |||
| EBIT | 13.96% | 22.79% | |||
| EBITDA | 13.63% | 23.70% | |||
| EPS Basic | 26.30% | 18.43% | |||
| Normalized Basic EPS | 19.01% | 23.86% | |||
| EPS Diluted | 26.30% | 18.43% | |||
| Normalized Diluted EPS | 19.01% | 23.86% | |||
| Average Basic Shares Outstanding | 23.49% | 0.26% | |||
| Average Diluted Shares Outstanding | 23.49% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||